Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arrowhead Pharmaceuticals

36.54
-0.9600-2.56%
Post-market: 36.48-0.0600-0.16%17:12 EDT
Volume:2.43M
Turnover:89.41M
Market Cap:5.05B
PE:-32.10
High:37.87
Open:37.58
Low:36.29
Close:37.50
52wk High:39.42
52wk Low:9.57
Shares:138.26M
Float Shares:118.91M
Volume Ratio:1.10
T/O Rate:2.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1384
EPS(LYR):-5.0048
ROE:-37.11%
ROA:-5.96%
PB:9.67
PE(LYR):-7.30

Loading ...

Arrowhead Pharmaceuticals Applies to New Zealand Regulator for Trial of ARO-DIMER-PA to Treat Mixed Hyperlipidemia

MT Newswires Live
·
Yesterday

BRIEF-Arrowhead Pharmaceuticals Files CTA For Investigational Aro-Dimer-PA

Reuters
·
Yesterday

Arrowhead Pharmaceuticals Files Cta for Investigational Aro-Dimer-Pa – the First Dual Functional Rnai Therapeutic for the Treatment of Mixed Hyperlipidemia

THOMSON REUTERS
·
Yesterday

What Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) 29% Share Price Gain Is Not Telling You

Simply Wall St.
·
Yesterday

Arrowhead Pharmaceuticals Chief Medical Officer James C. Hamilton Reports Sale of Common Shares

Reuters
·
Oct 04

4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals

Benzinga_recent_news
·
Sep 29

Piper Sandler Remains a Buy on Arrowhead Pharmaceuticals (ARWR)

TIPRANKS
·
Sep 23

Arrowhead Pharmaceuticals: Strategic Advancements and Promising Pipeline Drive Buy Rating

TIPRANKS
·
Sep 15

Update: Arrowhead Pharmaceuticals Sues Ionis Pharmaceuticals Over Plozasiran Patent Dispute

MT Newswires Live
·
Sep 12

Arrowhead files complaint for declaratory judgment against Ionis

TIPRANKS
·
Sep 11

Arrowhead Pharmaceuticals: Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals

THOMSON REUTERS
·
Sep 11

Arrowhead Pharmaceuticals Files Suit Against Ionis Pharmaceuticals Over Patent Dispute on Investigational Drug Plozasiran

Reuters
·
Sep 11

Arrowhead Pharmaceuticals Requests Regulatory Clearance for Tauopathies Phase 1/2a Study

MT Newswires Live
·
Sep 10

BRIEF-Arrowhead Seeks Approval to Begin ARO-MAPT Alzheimer’s Trial

Reuters
·
Sep 10

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of Aro-Mapt for the Treatment of Alzheimer’s Disease and Other Tauopathies

THOMSON REUTERS
·
Sep 10

Arrowhead Pharmaceuticals' Chief Medical Officer James C. Hamilton Reports Disposal of Common Shares

Reuters
·
Sep 05

Arrowhead Pharmaceuticals Price Target Maintained With a $80.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 03

Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday

Benzinga_recent_news
·
Sep 02

Arrowhead Pharmaceuticals Shares up 1.2% Premarket After Co Inks $2 Bln Deal With Novartis for License to Neuromuscular Therapy

THOMSON REUTERS
·
Sep 02

Arrowhead Pharmaceuticals Eligible for Up to $2 Billion in Potential Milestone Payments Under New Novartis Deal

MT Newswires Live
·
Sep 02